BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company dedicated to developing novel immunotherapies to transform cancer care. The company's mission is to enhance the lives of cancer patients, particularly those with breast cancer who have limited treatment options, by harnessing the body's immune system to fight cancer. BriaCell maintains its corporate headquarters in West Vancouver, British Columbia, Canada, with a significant operational presence in Philadelphia, Pennsylvania, USA.

The company's key product candidates include Bria-IMT™, its lead asset, which is a patented, off-the-shelf, cell-based targeted immunotherapy currently in a pivotal Phase 3 clinical study for metastatic breast cancer, having received FDA Fast Track designation. Additionally, BriaCell is developing Bria-OTS™ and Bria-OTS+™, personalized off-the-shelf immunotherapies undergoing Phase 1/2 clinical trials for metastatic breast cancer, prostate cancer, and other solid tumors. The company's pipeline also includes a soluble CD80 protein therapeutic, which acts as both an immune system stimulator and an immune checkpoint inhibitor, with an exclusive license for this asset held by its majority-owned subsidiary, BriaPro Therapeutics Corp.

Recent notable developments for BriaCell include the closing of an asset purchase transaction with BriaPro Therapeutics Corp. for an exclusive soluble CD80 license in March 2026. In February 2026, the company received a positive recommendation from the Data Safety Monitoring Board (DSMB) for its Phase 3 study in metastatic breast cancer. BriaCell also presented robust anti-cancer activity data for Bria-OTS+™ in preclinical models in April 2026. Dr. William V. Williams serves as the President and Chief Executive Officer. The company is positioned as a high-risk, high-reward clinical-stage oncology firm, with its future trajectory largely dependent on the outcomes of its ongoing clinical trials.